SK Bioscience Terminates High-Efficiency Influenza Vaccine Production Technology Transfer Agreement
[Asia Economy Reporter Gong Byung-sun] SK Bioscience announced on the 9th that Sanofi Pasteur, the vaccine subsidiary of the Sanofi Group, has notified the termination of the technology transfer agreement for high-efficiency influenza vaccine production using cell culture method, which was signed on February 12, 2018.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The agreement was signed before SK Bioscience was spun off from SK Chemicals.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
